News
Public · Published
The iPhone effect in healthcare: How Mounjaro is rewriting the economics of India's pharma market
Eli Lilly's patented Mounjaro has become India's top-selling drug by sales, overtaking GlaxoSmithKline's Augmentin. The article links the shift to rising demand for GLP-1 medicines for weight loss and diabetes, and says generic semaglutide volumes surged after Novo Nordisk's patent expired in March 2026.
Published:
Updated:
What happened
Eli Lilly's patented Mounjaro has become India's top-selling drug by sales, overtaking GlaxoSmithKline's Augmentin. The article links the shift to rising demand for GLP-1 medicines for weight loss and diabetes, and says generic semaglutide volumes surged after Novo Nordisk's patent expired in March 2026.
Confirmed
Global impact / market context
The change suggests Indian drugmakers may need to compete on more than low prices and large volumes. If patients pay more for trusted brands, delivery systems, and better outcomes, companies that build those strengths could gain sales, while firms relying mainly on inexpensive generics may face pressure.
Analyst inference
The article describes a market balancing affordability with growing interest in newer therapies. Generic semaglutide is priced from Rs.1,850 to Rs.8,000 a month, yet volumes have surged. That combination indicates demand can expand despite significant costs, but does not show that premium treatments are affordable to most patients.
Analyst inference
What to watch
- Watch whether Mounjaro retains its sales lead and whether GLP-1 medicines continue gaining demand, since sustained purchases would support the article's suggested shift in treatment preferences. Analyst inference
- Track generic semaglutide volumes and monthly prices after the March 2026 patent expiry; rising use at these prices would indicate that affordability is not the only purchase driver. Analyst inference
- Look for Indian drugmakers investing in recognizable brands, medicine delivery systems, or treatment support; these are the capabilities the article identifies as possible sources of advantage. Analyst inference
Evidence
- Original source link unavailable